... a steady stream of studies have warned against aspirin use in some of the key primary-prevention populations, including patients with asymptomatic atherosclerosis, type 2 diabetes, and peripheral artery disease.
Most striking of all was the May 2009 meta-analysis, ... The Lancet paper found that while aspirin used for primary prevention may reduce the risk of nonfatal ischemic events, these benefits are offset by higher bleeding, leaving no net effect on vascular mortality.Dr. Eric Topol of Scripps Clinic La Jolla, Calif., adds:
... now there are, just in this country alone, literally tens of millions of people taking low-dose aspirin that probably there is no basis for.The 2002 BMJ article, as originally printed, argued for some heart benefits of aspirin but not for all patients. It said, including the typo:
... It's really become kind of a consumer norm. As an outgrowth of the BMJ study in particular, aspirin has been advocated widely in the media. It's not just the cardiologists and family doctors who are making recommendations, it's magazines and newspapers and websites. It's all over the place."
For most healthy individuals, however, for whom the risk of a vascular event is likely to be substantially less than 1% a year, daily aspirin may well be appropriate." A correction swiftly issued by the BMJ noted that final word should, in fact, be inappropriate.HeartWire also calls out Bayer (BAY.DE)'s web site for aspirin, which it calls "an immodest homepage for a drug that, at least in the primary-prevention arena, has weathered a less-than-wonderful year." The site is indeed over the top and perhaps should be examined by the FDA for accuracy. Among the headlines:
- "Expect Wonders"
- "Heart Health Advantage"
- "You Can Do More to Protect Your Heart!"
Bayer has a history of mismarketing aspirin. In October 2008 the FDA cited Bayer for marketing unapproved aspirin drugs, one of which was Bayer Aspirin With Heart Advantage.